SecBot SecBot
6-K ·Filed Nov 6, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 6/10
Horizonweeks Processed10d 6h ago SEC0001193125-26-451904
Notable filing: 6-K
Actionable Insight ▲ Bullish

The EC decision on marketing authorization is imminent (Q4 2026). Approval would trigger a first EU launch in Germany in Q1 2027, opening a new revenue stream. Monitor the EC's final decision and subsequent launch execution.

DirectionBullish
Confidencehigh
Horizonweeks

YUVIWEL

◆ Mixed Named in this 6-K
Impact
Phase
Approved (FDA Accelerated Approval, February 2026)
Time to market
Already approved and commercially available in the US (launched April 2026). EMA approval in Europe is pending with no publicly confirmed date.
Next catalyst
None dated

What to watchThe binary approval catalyst has passed. Investors should now watch the commercial ramp (prescription trends, payer access, revenue contribution in upcoming quarterly reports) and any announcement of the confirmatory trial timeline or EMA filing date. The weekly-vs-daily dosing advantage is real, but first-mover BioMarin's Voxzogo ($927M in 2025 sales) is entrenched.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$259.85
T+0 close · Nov 6, 2026 · via day close
Latest settled
+4.57%
T+5 · $271.73
Vs SPY
+6.26%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $259.85entry
  2. T+1 · 7d ago −1.25%α −0.89% · $256.59
  3. T+5 · 16h ago +4.57%α +6.26% · $271.73
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma announced that the EMA's COMP adopted a positive opinion recommending maintenance of orphan medicinal product designation for TransCon CNP (navepegritide) for achondroplasia in children. This follows the CHMP's positive opinion recommending marketing authorization. The final EC decision on the MAA is expected in Q4 2026, with a first EU launch (YUVIWEL) in Germany targeted for Q1 2027.

Key Facts

  • EMA COMP adopted positive opinion recommending maintenance of orphan medicinal product designation for TransCon CNP (navepegritide) for achondroplasia in children.
  • Orphan designation would provide 10 years of orphan market exclusivity upon final adoption by the European Commission.
  • CHMP previously issued a positive opinion recommending marketing authorization for TransCon CNP in the EU for achondroplasia in children aged 2 and older.
  • Final EC decision on the MAA is expected during Q4 2026.
  • First EU launch under brand name YUVIWEL in Germany expected in Q1 2027.

Financial Impact

Orphan market exclusivity for 10 years in EU for achondroplasia treatment; launch in Germany targeted for Q1 2027. No financial figures stated.

revenue

Risk Factors

  • EC may not adopt the COMP opinion or grant marketing authorization.
  • Launch could be delayed by pricing, reimbursement, or manufacturing challenges.
  • Competitive developments or safety findings could impact commercial uptake.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-451904
Document: 0001193125-26-451904-index-headers.html0001193125-26-451904
Document: 0001193125-26-451904-index.html0001193125-26-451904
Document: 0001193125-26-451904.txt0001193125-26-451904
Earnings Context (Synthetic; results releases only)0001193125-26-451904

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Viewing Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026